Xencor (XNCR) Long-Term Investments (2015 - 2024)
Xencor (XNCR) reported Long-Term Investments of $43.8 million for Q2 2024, down 31.82% year-over-year from $64.2 million in Q3 2023, and up 0.51% quarter-over-quarter from $43.6 million in Q1 2024.
Xencor (XNCR) Long-Term Investments (2015 - 2024) Analysis & Trends
Xencor (XNCR) has 10 years of Long-Term Investments data on file, last reported at $43.8 million in Q2 2024.
- Long-Term Investments for Q2 2024 came in at $43.8 million, down 31.82% year-over-year; the trailing twelve-month figure through Jun 2024 was $43.8 million (down 31.82% YoY), and the FY2023 annual result was $64.2 million, up 18.07% from the prior year.
- Long-Term Investments improved to $43.8 million in Q2 2024 per XNCR's latest filing, from $43.6 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $64.2 million in Q2 2023 and troughed at $1.1 million in Q2 2020.
- A 5-year average of $38.6 million and a median of $35.0 million in 2020 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2020 and 2023: Long-Term Investments plunged 99.05% in 2020, then jumped 106.3% in 2023.
- A 5-year view of Long-Term Investments shows it stood at $16.1 million in 2020, then jumped by 94.52% to $31.3 million in 2021, then jumped by 73.96% to $54.4 million in 2022, then grew by 18.07% to $64.2 million in 2023, then plunged by 31.82% to $43.8 million in 2024.
- Business Quant data shows XNCR's Long-Term Investments at $43.8 million in Q2 2024, $43.6 million in Q1 2024, and $64.2 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 43.78 Mn |
| Mar 31, 2024 | 43.56 Mn |
| Dec 31, 2023 | 64.21 Mn |
| Sep 30, 2023 | 64.21 Mn |
| Jun 30, 2023 | 64.21 Mn |
| Mar 31, 2023 | 54.21 Mn |
| Dec 31, 2022 | 54.38 Mn |
| Sep 30, 2022 | 31.12 Mn |
| Jun 30, 2022 | 31.12 Mn |
| Mar 31, 2022 | 31.26 Mn |
| Dec 31, 2021 | 31.26 Mn |
| Sep 30, 2021 | 16.58 Mn |
| Dec 31, 2020 | 16.07 Mn |
| Sep 30, 2020 | 31.77 Mn |
| Jun 30, 2020 | 1.15 Mn |
| Mar 31, 2020 | 38.23 Mn |
| Dec 31, 2019 | 71.53 Mn |
| Sep 30, 2019 | 74.00 Mn |
| Jun 30, 2019 | 120.97 Mn |
| Mar 31, 2019 | 172.47 Mn |